Clinical Trials
25 trialsNCT01552434 2026-05-15
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT07584499 2026-05-13
MRG003
Sun Yat-sen University
Phase 1 Recruiting
NCT05283330 2026-04-30
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med LLC
Phase 1 Recruiting
NCT07543055 2026-04-21
A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
Regeneron Pharmaceuticals
Phase 1 Not yet recruiting
NCT05861947 2026-04-17
JIVAN
Aurigene Discovery Technologies Limited
Phase 1 Terminated
NCT07277413 2026-04-03
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
Phase 1 Recruiting
NCT06022029 2025-12-24
ON-5001
OncoNano Medicine, Inc.
Phase 1 Recruiting
NCT04777994 2025-12-23
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Calico Life Sciences LLC
Phase 1 Recruiting
NCT03861403 2023-11-30
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Leap Therapeutics, Inc.
Phase 1 Terminated
NCT03758781 2023-04-14
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02035358 2022-04-06
Immunotherapy Study for Metastatic Renal Cell Cancer
Lumos Pharma
Phase 1 Completed
NCT03538028 2020-10-30
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Corporation
Phase 1 Completed
NCT01331135 2020-05-29
Aflac ST0901
Emory University
Phase 1 Completed
NCT01478685 2019-11-12
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
Celgene
Phase 1 Completed
NCT00509691 2017-05-09
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
University of Louisville
Phase 1 Completed
NCT00604526 2016-01-05
High Dose Rate Prostate Brachytherapy as Salvage for Locally Recurrent Prostate Cancer Previously Treated With External Beam Radiotherapy
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00161187 2015-11-06
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Rutgers, The State University of New Jersey
Phase 1 Completed
NCT01495663 2015-02-26
Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned
Cellectar Biosciences, Inc.
Phase 1 Completed
NCT00441337 2015-02-20
MDX1106-01
Bristol-Myers Squibb
Phase 1 Completed
NCT00769613 2013-12-18
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00012181 2013-07-02
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Completed
NCT00101270 2013-06-05
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Completed
NCT00569283 2013-03-26
Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
National Cancer Institute (NCI)
Phase 1 Completed
NCT01458847 2012-11-12
Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer
BioCis Pharma Ltd
Phase 1 Completed
NCT00120939 2009-04-03
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
Pharmacyclics LLC.
Phase 1 Completed